DBV Technologies (DBVT +2.8%) says the Food and Drug Administration has accepted the Biologics License Application for its Viaskin peanut immunotherapy for the treatment of peanut-allergic children aged 4-11; shares are halted.
If approved, Viaskin Peanut would be the first and
only epicutaneous immunotherapy indicated for the potentially
life-threatening condition in children.
DBV says the FDA plans to hold an advisory
committee meeting to discuss the application, with a target action date
of Aug. 5, 2020.
https://seekingalpha.com/news/3504026-fda-accepts-bla-filing-dbv-techs-peanut-allergy-treatment
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.